837 studies found for:
Open Studies | "Stem Cell Transplantation"
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Not yet recruiting |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
|
||||
| 2 | Recruiting |
Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma
|
||||
| 3 | Recruiting |
Difference Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With Spinal Cord Injury in China
|
||||
| 4 | Recruiting |
Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors
|
||||
| 5 | Recruiting |
Safety and Efficacy of Stem Cell Transplantation for Treatment of Liver Cirrhosis
|
||||
| 6 | Recruiting |
5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)
|
||||
| 7 | Recruiting |
Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, and High-Dose Combination Chemotherapy Followed By Peripheral Blood Stem Cell Transplant in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
|
||||
| 8 | Recruiting |
Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma
|
||||
| 9 | Unknown † |
Safety and Efficacy Study of Autologous Stem Cell Transplantation for Early Onset Type I Diabetes Mellitus
|
||||
| 10 | Recruiting |
Efficacy and Safety Study of Autologous Hematopoietic Stem Cell Transplantation to Treat New Onset Type 1 Diabetes
|
||||
| 11 | Recruiting |
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
|
||||
| 12 | Recruiting |
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
|
||||
| 13 | Recruiting |
Autologous Peripheral Blood Stem Cell Transplantation With In Vivo Purging as an Alternate Stem Cell Transplantation Program for Pts w/AML in 1st & 2nd Complete Remission w/no HLA Matched Related Donor
|
||||
| 14 | Recruiting |
Haematopoietic Stem Cell Transplantation (HSCT) in Comparison to Conventional Consolidation Therapy for Patients With Acute Myeloid Leukemia (AML) (Intermediate Risk) <= 60y. After First CR
|
||||
| 15 | Recruiting |
Study of Allogeneic Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
|
||||
| 16 | Recruiting |
Allogeneic Genoidentical Stem Cell Transplantation in Children With Sickle-cell Anemia and Cerebral Vasculopathy
|
||||
| 17 | Recruiting |
Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus
|
||||
| 18 | Recruiting |
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
|
||||
| 19 | Recruiting |
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
|
||||
| 20 | Recruiting |
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
|
† Indicates status has not been verified in more than two years
